View Older Stories View More Recent Stories

Jul 9, 2024 03:01AM Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
Jul 2, 2024 08:01AM Mainz Biomed (MYNZ) Issues Half Year 2024 Corporate Update
Jul 2, 2024 08:01AM Mainz Biomed Provides Half Year 2024 Corporate Update
Jun 3, 2024 08:01AM Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
May 31, 2024 05:01PM Mainz Biomed Reports Results of 2024 Annual General Meeting
May 28, 2024 08:01AM Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
May 20, 2024 08:01AM Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
May 7, 2024 08:01AM Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
Apr 25, 2024 09:29AM Mainz Biomed (MYNZ) Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm
Apr 25, 2024 09:29AM Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Co
Apr 9, 2024 08:01AM Mainz Biomed Reports Full Year 2023 Financial Results
Mar 19, 2024 08:01AM Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
Mar 18, 2024 08:01AM Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
Mar 12, 2024 08:01AM Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
Mar 5, 2024 08:01AM Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
Feb 27, 2024 08:01AM Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
Feb 22, 2024 08:02AM Mainz Biomed (MYNZ) Enters Distribution Partnership with Praxisdienst for ColoAlert
Feb 22, 2024 08:01AM Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
Feb 21, 2024 08:01AM Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
Feb 6, 2024 08:01AM Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany
Feb 6, 2024 08:01AM Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany
Jan 11, 2024 08:01AM Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
Jan 9, 2024 08:02AM Mainz Biomed (MYNZ) Issues Year-End Corporate Review
Jan 9, 2024 08:01AM Mainz Biomed Provides Year-End Corporate Review 2023
Dec 19, 2023 08:01AM Mainz Biomed (MYNZ) and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
Dec 19, 2023 08:01AM Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
Dec 12, 2023 08:01AM Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
Dec 5, 2023 09:01AM Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
Nov 29, 2023 08:01AM Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
Nov 20, 2023 08:01AM Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference
Nov 16, 2023 08:03AM Mainz Biomed (MYNZ) Reports Q3 Results
Nov 16, 2023 08:01AM Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Nov 15, 2023 09:01AM Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering
Nov 13, 2023 09:01AM Mainz Biomed (MYNZ) Prices $5M Share Offering at $1.20/sh
Nov 13, 2023 09:00AM Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering
Nov 9, 2023 08:01AM Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
Nov 7, 2023 08:01AM Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA
Oct 31, 2023 08:01AM Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper
Oct 26, 2023 08:05AM Mainz Biomed (MYNZ) Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
Oct 26, 2023 08:01AM Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
Oct 18, 2023 08:01AM Mainz Biomed Presents Groundbreaking Results of ColoFuture Study
Oct 11, 2023 08:01AM Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
Oct 5, 2023 08:01AM Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit 
Oct 4, 2023 08:01AM Mainz Biomed (MYNZ) Announces Live Launch of ColoAlert with Bioclinica in Romania
Oct 4, 2023 08:01AM Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania
Sep 27, 2023 08:01AM Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
Sep 20, 2023 03:01AM Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference 
Sep 13, 2023 05:40AM Mainz Biomed's (MYNZ) ColoFuture Study Reports Topline Data Showing Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
Sep 13, 2023 03:01AM Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advan
Sep 5, 2023 05:31AM Mainz Biomed (MYNZ) Partners with Ärztliches Labor Dr. Buhlmann, Expands Footprint in German Market
View More Recent Stories View Older Stories